{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T13:30:39Z","timestamp":1688736639902},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40256-018-0310-3","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T07:46:59Z","timestamp":1541663219000},"page":"195-201","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Non-vitamin K Oral Anticoagulants Use in a Tertiary Care Center in the USA: A Chart Review of 909 Patients"],"prefix":"10.1007","volume":"19","author":[{"given":"Marwan","family":"Sheikh-Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"issue":"16","key":"310_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"issue":"16","key":"310_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jacc.2016.01.072","volume":"67","author":"C Becattini","year":"2016","unstructured":"Becattini C, Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol. 2016;67(16):1941\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"310_CR3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/17425255.2016.1225037","volume":"12","author":"C Voukalis","year":"2016","unstructured":"Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol. 2016;12(12):1445\u201361.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"310_CR4","doi-asserted-by":"crossref","unstructured":"Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, D\u00edaz-Peromingo JA, N\u00fa\u00f1ez MJ, Ca\u00f1as I, Mastroiacovo D, De Sousa MS, Monreal M, RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost. 2017;117(02):382-9.","DOI":"10.1160\/TH16-07-0494"},{"issue":"23","key":"310_CR5","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","volume":"69","author":"X Yao","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"310_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, See LC, Kuo CF. Association between use of non-vitamin k oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250\u20139.","journal-title":"JAMA"},{"key":"310_CR7","volume-title":"Lexi-Drugs\u00ae","author":"Lexicomp, Inc.","year":"2018","unstructured":"Lexicomp, Inc. Lexi-Drugs\u00ae. Hudson: Lexicomp, Inc.; 2018."},{"issue":"6","key":"310_CR8","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1161\/JAHA.113.000535","volume":"2","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2(6):e000535.","journal-title":"J Am Heart Assoc."},{"issue":"14","key":"310_CR9","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"AJ Camm","year":"2015","unstructured":"Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2015;37(14):1145\u201353.","journal-title":"Eur Heart J"},{"key":"310_CR10","doi-asserted-by":"crossref","unstructured":"Andrade JG, Hawkins NM, Fordyce CB, Deyell MW, Er L, Djurdjev O, Macle L, Virani SA, Levin A. Variability in non-vitamin K antagonist oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae. Can J Cardiol. 2018.","DOI":"10.1016\/j.cjca.2018.04.019"},{"issue":"6","key":"310_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","volume":"14","author":"K Martin","year":"2016","unstructured":"Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308\u201313.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"310_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10067-015-3030-y","volume":"35","author":"F Signorelli","year":"2016","unstructured":"Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol. 2016;35(3):801\u20135.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"310_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105(5):412\u201320.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"310_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","volume":"133","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352\u201360.","journal-title":"Circulation"},{"key":"310_CR15","doi-asserted-by":"publisher","first-page":"i2868","DOI":"10.1136\/bmj.i2868","volume":"353","author":"J Focks","year":"2016","unstructured":"Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868.","journal-title":"BMJ"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-0310-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:17:32Z","timestamp":1573172252000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-0310-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-0310-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"8 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marwan Sheikh-Taha and Mary E. Deeb declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}